IDYA Overview

IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.

Wall Street analysts forecast IDYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDYA is49.86 USD with a low forecast of 30.00 USD and a high forecast of 79.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

IDEAYA Biosciences Inc revenue for the last quarter amounts to 10.88M USD, increased 55.37

IDEAYA Biosciences Inc. EPS for the last quarter amounts to -0.94 USD, decreased -36.91

IDEAYA Biosciences Inc (IDYA) has 145 emplpoyees as of April 23 2026.

Today IDYA has the market capitalization of 2.78B USD.